Anke Loregger, Matthijs Raaben, Josephine Tan, Saskia Scheij, Martina Moeton, Marlene van den Berg, Hila Gelberg-Etel, Elmer Stickel, Joseph Roitelman, Thijn Brummelkamp, Noam Zelcer. A haploid mammalian genetic screen identifies UBXD8 as a key determinant of HMGCR degradation and cholesterol biosynthesis. ATVB 2017; In press

        Anthony Alioui, Julie Dufour, Valerio Leoni, Anke Loregger, Martina Moeton, Luigi Luliano, Chiara Zerbinati, Amandine Septier, Pierre Val, Allan Fouache, Vincenzo Russo, David H. Volle, Jean-Marc A. Lobaccaro,  Noam Zelcer, Silvère Baron. Liver X Receptors constrain tumor development and metastasis dissemination in PTEN-deficient prostate cancer. Nat Comm 2017; In Press

        Hakonen JE, Sorrentino V, Avagliano Trezza R, de Wissel MB, van den Berg M, Bleijlevens B, van Ruissen F, Distel B, Baas F, Zelcer N, Weterman MAJ. LRSAM1-mediated ubiquitylation is disrupted in axonal Charcot-Marie-Tooth disease 2P. Hum Mol Genet 2017;26:2034–2041. PDF

        Nelson JK, Koenis DS, Scheij S, Cook ECL, Moeton M, Santos A, Lobaccaro J-MA, Baron S, Zelcer N. EEPD1 Is a Novel LXR Target Gene in Macrophages Which Regulates ABCA1 Abundance and Cholesterol Efflux. ATVB; 2017;37:423–432. PDF

        Loregger A, Nelson JK, Zelcer N. Assaying Low-Density-Lipoprotein (LDL) Uptake into Cells. In: Gelissen IC, Brown AJ, eds. Cholesterol Homeostasis New York, NY: Springer New York; 2017. p. 53–63. PDF

        Cook ECL, Nelson JK, Sorrentino V, Koenis D, Moeton M, Scheij S, Ottenhoff R, Bleijlevens B, Loregger A, Zelcer N. Identification of the ER-resident E3 ubiquitin ligase RNF145 as a novel LXR-regulated gene. PLoS ONE 2017;12:e0172721. PDF

        Van Loon NM, Zelcer N. Idolizing the clearance of Amyloid-β by microglia. Ann Transl Med 2016;4:536–536. PDF

        Tol MJ, Ottenhoff R, van Eijk M, Zelcer N, Aten J, Houten SM, Geerts D, van Roomen C, Bierlaagh MC, Scheij S, Hoeksema MA, Aerts JM, Bogan JS, Dorn GW, Argmann CA, Verhoeven AJ. A PPARγ-Bnip3 Axis Couples Adipose Mitochondrial Fusion-Fission Balance to Systemic Insulin Sensitivity. Diabetes 2016;65:2591–2605. PDF

        Nelson JK, Cook ECL, Loregger A, Hoeksema MA, Scheij S, Kovacevic I, Hordijk PL, Ovaa H, Zelcer N. De-ubiquitylase inhibition reveals LXR-independent transcriptional regulation of the E3 ubiquitin ligase IDOL and lipoprotein uptake. J Biol Chem. 2016;291:4813-4825. PDF

        Nelson JK, Sorrentino V, Avagliano-Trezza R, Heride C, Urbe S, Distel B, Zelcer N. The deubiquitylase USP2 regulates the LDLR pathway by counteracting the E3-ubiquitin ligase IDOL. Circ Res. 2016;118:410-419. PDF

        Lu X, Meima ME, Nelson JK, Sorrentino V, Loregger A, Scheij S, Dekkers DH, Mulder

        MT, Demmers JA, Dallinga-Thie GM, Zelcer N*, Danser AJ*. Identification of the

        (Pro)renin Receptor as a Novel Regulator of Low-Density Lipoprotein Metabolism.

        Circ Res. 2016;118:222-229. PDF


        Loregger A, Cook ECL, Nelson JK, Moeton M, Sharpe LJ, Engberg S, Karimova M,

        Lambert G, Brown AJ, Zelcer N. A MARCH6 and IDOL E3 ubiquitin ligase circuit

        uncouples cholesterol synthesis from lipoprotein uptake in hepatocytes. Mol Cell Biol.

        2015;36:285-294. PDF


        De Boussac H, Maqdasy S, Trousson A, Zelcer N, Volle DH, Lobaccaro J-MA, Baron S. Enolase is regulated by Liver X Receptors. Steroids. 2015;99:266-271. PDF

        Kurakula K, Sommer D, Sokolovic M, Moerland PD, Scheij S, van Loenen PB, Koenis DS, Zelcer N, van Tiel CM, de Vries CJM. LIM-only protein FHL2 is a Positive Regulator of Liver X Receptors in Smooth Muscle Cells involved in Lipid Homeostasis. Mol Cell Biol. 2015;35:52-62. PDF

        Sharpe L, Cook E, Zelcer N*, Brown A*. The UPS and downs of cholesterol homeostasis, TIBS, 2014;39:527-535.  PDF

        Kizhakkedath P, Loregger A, John A, Bleijlevens B, Al-Blooshi AS, Al-Hosani AH, Al-Nuaimi AM, Al-Gazali L, Zelcer N, Ali BR. Impaired trafficking of the very low density lipoprotein receptor caused by missense mutations associated with dysequilibrium syndrome, Biochim Biophys Acta Mol. Cell. Res, 2014;1843:2871-2877. PDF

        Fouchier SW, Dallinga-Thie GM, Meijers JCM, Zelcer N, Kastelein JJP, Defesche JC, Hovingh GK. Mutations in STAP1 Are Associated With Autosomal Dominant Hypercholesterolemia. Circ Res. 2014;115:552–555. PDF

        Zelcer N, Westerterp M. Adeno-associated viruses as a method to induce atherosclerosis in mice and hamsters. Circ Res. 2014;114:1672–1674. PDF

        Zelcer N*, Sharpe L, Loregger A, Kristiana I, Cook E, Phan L, Stevenson J, Brown A*. The E3 ubiquitin ligase MARCH6 degrades squalene monooxygenase and affects 3-hydroxy-3-methyl-glutaryl coenzyme A reductase and the cholesterol synthesis pathway. Mol Cell Biol. 2014;34:1262–1270. PDF

        Bogie J, Jorissen W, Mailleux J, Nijland P, Zelcer N, Vanmierlo T, Van Horssen J, Hellings N, Hendriks J. Myelin alters the inflammatroy phenotype of macrophages by activating PPARs, Acta Neuropathologica Communications. 2013, 1:43 PDF

        Sorrentino V, Nelson J, Maspero E, Marques A, Scheer L, Polo S, Zelcer N. The LXR-IDOL axis defines a clathrin, caveeolae, and dynamin-independent endocytic route for LDLR internalization and lysosomal degradation. J Lipid Res. 2013;54:2174–2184. PDF

        Pietiainen V, Vassilev B, Blom T, Wang W, Nelson J, Bittman R, Back N, Zelcer N, Ikonen E. NDRG1 functions in LDL receptor trafficking by regulating endosomal recycling and degradation. J Cell Sci. 2013;126:3961–3971. PDF

        Sorrentino V, Fouchier SW, Motazacker MM, Nelson JK, Defesche JC, Dallinga-Thie GM, Kastelein JJP, Kees Hovingh G, Zelcer N. Identification of a loss-of-function inducible degrader of the low-density lipoprotein receptor variant in individuals with low circulating low-density lipoprotein. Eur Heart J. 2013;34:1292–1297. PDF

        Motazacker MM, Pirruccello J, Huijgen R, Do R, Gabriel S, Peter J, Kuivenhoven JA, Defesche JC, Kastelein JJP, Hovingh GK, Zelcer N, Kathiresan S, Fouchier SW. Advances in genetics show the need for extending screening strategies for autosomal dominant hypercholesterolaemia. Eur Heart J. 2012 Jun;33(11):1360–1366. PDF

        Sorrentino V, Zelcer N. Post-transcriptional regulation of lipoprotein receptors by the E3-ubiquitin ligase inducible degrader of the low-density lipoprotein receptor. Curr. Opin. Lipidol. 2012 Jun;23(3):213–219. PDF

        Weterman MAJ, Sorrentino V, Kasher PR, Jakobs ME, van Engelen BGM, Fluiter K, de Wissel MB, Sizarov A, Nürnberg G, Nürnberg P, Zelcer N, Schelhaas HJ, Baas F. A frameshift mutation in LRSAM1 is responsible for a dominant hereditary polyneuropathy. Hum. Mol. Genet. 2012 Jan 15;21(2):358–370. PDF

        Do HT, Tselykh TV, Makela J, Ho TH, Olkkonen VM, Bornhauser BC, Korhonen L, Zelcer N, Lindholm D. Fibroblast growth factor-21 (FGF21) regulates low-density lipoprotein receptor (LDLR) levels in cells via the E3-ubiquitin ligase Mylip/Idol and the Canopy2 (Cnpy2)/Mylip-interacting saposin-like protein (Msap). J. Biol. Chem. 2012;287(16):12602–12611. PDF

        Sorrentino V, Scheer L, Santos A, Reits E, Bleijlevens B, Zelcer N. Distinct functional domains contribute to degradation of the low density lipoprotein receptor (LDLR) by the E3 ubiquitin ligase inducible Degrader of the LDLR (IDOL). J Biol Chem. 2011 Aug 26;286(34):30190–30199. PDF

        Weissglas-Volkov D, Calkin AC, Tusie-Luna T, Sinsheimer JS, Zelcer N, Riba L, Tino AMV, Ordoñez-Sánchez ML, Cruz-Bautista I, Aguilar-Salinas CA, Tontonoz P, Pajukanta P. The N342S MYLIP polymorphism is associated with high total cholesterol and increased LDL receptor degradation in humans. J Clin Invest. 2011 Aug 1;121(8):3062–3071. PDF

        Scotti E, Hong C, Yoshinaga Y, Tu Y, Hu Y, Zelcer N, Boyadjian R, de Jong PJ, Young SG, Fong LG, Tontonoz P. Targeted disruption of the idol gene alters cellular regulation of the low-density lipoprotein receptor by sterols and liver x receptor agonists. Mol. Cell. Biol. 2011 May;31(9):1885–1893. PDF

        Hong C, Duit S, Jalonen P, Out R, Scheer L, Sorrentino V, Boyadjian R, Rodenburg KW, Foley E, Korhonen L, Lindholm D, Nimpf J, van Berkel TJC, Tontonoz P, Zelcer N. The E3 ubiquitin ligase IDOL induces the degradation of the low density lipoprotein receptor family members VLDLR and ApoER2. J Biol Chem. 2010 Jun 25;285(26):19720–19726. PDF

        A-Gonzalez N, Bensinger SJ, Hong C, Beceiro S, Bradley MN, Zelcer N, Deniz J, Ramirez C, Díaz M, Gallardo G, de Galarreta CR, Salazar J, Lopez F, Edwards P, Parks J, Andujar M, Tontonoz P, Castrillo A. Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity. 2009 Aug 21;31(2):245–258. PDF

        Zelcer N, Hong C, Boyadjian R, Tontonoz P. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science. 2009 Jul 3;325(5936):100–104. PDF

        Bensinger SJ, Bradley MN, Joseph SB, Zelcer N, Janssen EM, Hausner MA, Shih R, Parks JS, Edwards PA, Jamieson BD, Tontonoz P. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell. 2008 Jul 11;134(1):97–111. PDF

        Jiang Q, Lee CYD, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE. ApoE promotes the proteolytic degradation of Abeta. Neuron. 2008 Jun 12;58(5):681–693. PDF

        van de Wetering K, Zelcer N, Kuil A, Feddema W, Hillebrand M, Vlaming MLH, Schinkel AH, Beijnen JH, Borst P. Multidrug resistance proteins 2 and 3 provide alternative routes for hepatic excretion of morphine-glucuronides. Mol Pharmacol. 2007 Aug;72(2):387–394. PDF

        Zelcer N, Khanlou N, Clare R, Jiang Q, Reed-Geaghan EG, Landreth GE, Vinters HV, Tontonoz P. Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. Proc Natl Acad Sci USA. 2007 Jun 19;104(25):10601–10606. PDF

        Zelcer N, van de Wetering K, de Waart R, Scheffer GL, Marschall H-U, Wielinga PR, Kuil A, Kunne C, Smith A, van der Valk M, Wijnholds J, Elferink RO, Borst P. Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronides. J. Hepatol. 2006 Apr;44(4):768–775. PDF

        Borst P, Zelcer N, van de Wetering K. MRP2 and 3 in health and disease. Cancer Lett. 2006 Mar 8;234(1):51–61. PDF

        Zelcer N, Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest. 2006 Mar;116(3):607–614. PDF

        Borst P, Zelcer N, van de Wetering K, Poolman B. On the putative co-transport of drugs by multidrug resistance proteins. FEBS Lett. 2006 Feb 13;580(4):1085–1093. PDF

        Manautou JE, de Waart DR, Kunne C, Zelcer N, Goedken M, Borst P, Elferink RO. Altered disposition of acetaminophen in mice with a disruption of the Mrp3 gene. Hepatology. 2005 Nov;42(5):1091–1098. PDF

        Zelcer N, Tontonoz P. SUMOylation and PPARgamma: wrestling with inflammatory signaling. Cell Metab. 2005 Nov;2(5):273–275. PDF

        Pichler A, Zelcer N, Prior JL, Kuil AJ, Piwnica-Worms D. In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein. Clin. Cancer Res. 2005 Jun 15;11(12):4487–4494. PDF

        Zelcer N, van de Wetering K, Hillebrand M, Sarton E, Kuil A, Wielinga PR, Tephly T, Dahan A, Beijnen JH, Borst P. Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception. Proc Natl Acad Sci USA. 2005 May 17;102(20):7274–7279. PDF

        Wielinga P, Hooijberg JH, Gunnarsdottir S, Kathmann I, Reid G, Zelcer N, van der Born K, de Haas M, van der Heijden I, Kaspers G, Wijnholds J, Jansen G, Peters G, Borst P. The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Res. 2005 May 15;65(10):4425–4430. PDF

        Breedveld P, Zelcer N, Pluim D, Sönmezer O, Tibben MM, Beijnen JH, Schinkel AH, van Tellingen O, Borst P, Schellens JHM. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res. 2004 Aug 15;64(16):5804–5811. PDF

        Assem M, Schuetz EG, Leggas M, Sun D, Yasuda K, Reid G, Zelcer N, Adachi M, Strom S, Evans RM, Moore DD, Borst P, Schuetz JD. Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J Biol Chem. 2004 May 21;279(21):22250–22257. PDF

        Borst P, Balzarini J, Ono N, Reid G, de Vries H, Wielinga P, Wijnholds J, Zelcer N. The potential impact of drug transporters on nucleoside-analog-based antiviral chemotherapy. Antiviral Res. 2004 Apr;62(1):1–7 PDF.

        Cummings J, Zelcer N, Allen JD, Yao D, Boyd G, Maliepaard M, Friedberg TH, Smyth JF, Jodrell DI. Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins. Biochem. Pharmacol. 2004 Jan 1;67(1):31–39. PDF

        Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P. The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci USA. 2003 Aug 5;100(16):9244–9249. PDF

        Zelcer N, Huisman MT, Reid G, Wielinga P, Breedveld P, Kuil A, Knipscheer P, Schellens JHM, Schinkel AH, Borst P. Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J Biol Chem. 2003 Jun 27;278(26):23538–23544. PDF

        Reid G, Wielinga P, Zelcer N, de Haas M, Van Deemter L, Wijnholds J, Balzarini J, Borst P. Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol. 2003 May;63(5):1094–1103. PDF

        Zelcer N, Reid G, Wielinga P, Kuil A, van der Heijden I, Schuetz JD, Borst P. Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J. 2003 Apr 15;371(Pt 2):361–367. PDF

        Zelcer N, Saeki T, Bot I, Kuil A, Borst P. Transport of bile acids in multidrug-resistance-protein 3-overexpressing cells co-transfected with the ileal Na+-dependent bile-acid transporter. Biochem J. 2003 Jan 1;369(Pt 1):23–30. PDF

        Huisman MT, Smit JW, Crommentuyn KML, Zelcer N, Wiltshire HR, Beijnen JH, Schinkel AH. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS. 2002 Nov 22;16(17):2295–2301. PDF

        Burg D, Wielinga P, Zelcer N, Saeki T, Mulder GJ, Borst P. Inhibition of the multidrug resistance protein 1 (MRP1) by peptidomimetic glutathione-conjugate analogs. Mol Pharmacol. 2002 Nov;62(5):1160–1166. PDF

        Zelcer N, Saeki T, Reid G, Beijnen JH, Borst P. Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem. 2001 Dec 7;276(49):46400–46407. PDF

        Borst P, Zelcer N, van Helvoort A. ABC transporters in lipid transport. Biochim. Biophys. Acta. 2000 Jun 26;1486(1):128–144. PDF